The Phelan-McDermid Syndrome Foundation is sharing an important update with our community: Neuren’s Phase 3 clinical trial of NNZ-2951, known as the “Koala” study, is now active and listed on clinicaltrials.gov.  

This study is a Phase 3 randomized, double-blind, placebo-controlled clinical trial evaluating NNZ-2591 in children aged 3 to 12 years with Phelan-McDermid syndrome. This marks the first Phase 3 clinical trial conducted specifically in Phelan-McDermid syndrome, representing a significant milestone in the clinical trial pipeline for the community.